Lv1
66 积分 2022-11-26 加入
Burden of neurological disorders in China and its provinces, 1990–2021: Findings from the global burden of disease study 2021
4小时前
已完结
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
1天前
已完结
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
1天前
已完结
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
1天前
已完结
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
1天前
已完结
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
2天前
已完结
A new era for glioma therapy — targeting mutant IDH
2天前
已完结
Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
3天前
已完结
Histone H3 K27 alterations in central nervous system tumours: Challenges and alternative diagnostic approaches
3天前
已完结
Artificial intelligence and the evolution of pathology: Scaling from digital diagnostics to multimodal precision medicine
4天前
已完结
皖公网安备34019202002308
